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exacerbation recovery patterns in newly diagnosed 
or maintenance treatment-naïve patients with 
COPD: secondary analyses of TICarI 1 trial data
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of Kentucky College of Public health, 
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Background: Little is known about the recovery patterns from acute exacerbations of chronic 
obstructive pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve 
patients with COPD. This study describes the course of AECOPD in these patients at the time 
of treatment for the symptoms of acute respiratory tract infection (RTI).
Methods: This study was a secondary analysis of data from a 12-week, randomized clinical 
trial (TICARI 1) testing the efficacy and safety of once-daily tiotropium 18 µg maintenance 
therapy versus placebo in newly diagnosed or maintenance treatment-naïve COPD patients 
with acute RTI symptoms for #7 days. Patients received standard care for AECOPD and RTI. 
Due to under-recruitment, the trial ended early and hence was underpowered to detect treat-
ment differences. Data were pooled and exacerbation recovery patterns examined by using the 
EXAcerbation of Chronic Pulmonary Disease Tool (EXACT), forced expiratory volume in 
1 second, rescue medication use, COPD Assessment Test™, Functional Assessment of Chronic 
Illness Therapy–Short Form, and Work Productivity and Activity Impairment Questionnaire: 
Respiratory Symptoms.
Results: Of 140 patients, 73.6% had a prior COPD diagnosis without maintenance therapy; 
80.0% had moderate-to-severe airflow obstruction. In addition to study drug, 40.0% were 
prescribed pharmacologic therapy (corticosteroids [34.3%], antibiotics [16.4%], and short-
acting β
2
-adrenergic agonists [5.0%]) within ±7 days of randomization. Over 12 weeks, 78.6% 
exhibited symptomatic recovery (EXACT score) in a median of 5.0 days. Across all patients, 
49.3% recovered without relapse, 29.3% recovered and then relapsed, and 21.4% had persistent 
symptoms (recovery criteria unmet).
Conclusion: A substantial portion of newly diagnosed or maintenance treatment-naïve patients 
with COPD experience relapse or persistent symptoms following a clinic visit for AECOPD 
with symptoms of RTI. Whether initiating maintenance therapy could improve outcomes and 
reduce exacerbation risk requires further study.
Keywords: acute respiratory tract infection symptoms, acute exacerbation of chronic obstruc-
tive pulmonary disease, AECOPD, COPD Assessment Test™, EXACT, maintenance therapy, 
pulmonary function, tiotropium
Plain language summary
Little is known about recovery patterns from acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve patients. 
This study examined this process in patients with moderate-to-severe COPD with an acute 
respiratory tract infection (RTI) enrolled in a 12-week, randomized clinical trial (TICARI 1; 
NCT01483625), originally designed to examine the efficacy and safety of once-daily tiotro-
pium 18 µg in this population. Symptomatic recovery was assessed using the EXAcerbation 
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of Chronic Pulmonary Disease Tool (EXACT), a 14-item diary 
completed by patients each evening, to assess the severity of breath-
lessness, cough, sputum, chest symptoms, sleep disturbance, feeling 
week or tired, and feeling worried or concerned. Over 12 weeks, 
49.3% of patients recovered without a relapse, 29.3% recovered 
and subsequently relapsed, and 21.4% had persistent symptoms 
(ie, did not meet the recovery criteria). Results were consistent 
across health outcomes, including health status, dyspnea, activity 
limitation, and work productivity. The study findings suggest that a 
significant portion of newly diagnosed and treatment-naïve patients 
have difficulty recovering from an acute RTI. Further study of the 
short- and long-term effects of these events and the effectiveness 
of various treatment options is warranted.
Introduction
Chronic obstructive pulmonary disease (COPD) is often unde-
tected or under-diagnosed until it has progressed to more 
advanced stages.1 This may be due, in part, to difficulty 
recognizing that the symptoms, such as cough, sputum pro-
duction, and/or shortness of breath, may signal respiratory 
impairment in need of diagnosis and treatment. Patients may 
underestimate or understate their symptoms, assuming that 
they are due to normal aging, body weight, smoking, or other 
factors. Progressive airflow limitation may only become 
evident to the patient and clinician when the respiratory 
system is challenged by an acute respiratory tract infection 
(RTI). These events can be viewed as opportunities for 
clinicians to diagnose COPD and to initiate maintenance 
therapy in patients who are more aware of their condition 
and are at risk for repeated acute exacerbations of COPD 
(AECOPD).2–5
Little is known about AECOPD and the effect of treat-
ment in newly diagnosed and treatment-naïve patients with 
COPD. In studies of patients with an established COPD 
diagnosis, recovery times have been shown to be longer 
in individuals with moderate-to-severe airflow obstruction 
who have more pronounced decline in lung function during 
the event and, in some cases, recovery is incomplete.6 In a 
study of COPD patients with moderate-to-severe airflow 
obstruction, recovery time became longer and symptoms 
more frequent during an AECOPD as the disease progressed.3 
Patients with sudden onset of AECOPD were found to have 
more respiratory symptoms, but a shorter recovery time, 
compared with those with gradual onset of AECOPD.7
The extent to which the addition of COPD maintenance 
treatment to RTI treatment improves pulmonary function and 
alters the trajectory of recovery in maintenance treatment- 
naïve patients with COPD is unknown. Tiotropium, a long-
acting anticholinergic, has been shown to improve pulmonary 
function, relieve symptoms, and reduce exacerbation frequency 
in patients with stable COPD8–13 (ie, patients who were 
exacerbation free for 4 or 6 weeks prior to randomization). 
The Tiotropium In COPD patients with an Acute Respira-
tory Infection 1 (TICARI 1; ClinicalTrials.gov identifier: 
NCT01483625) trial was conducted to evaluate the efficacy 
and safety of tiotropium in maintenance treatment-naïve 
patients with COPD presenting to the outpatient clinic with 
symptoms of an acute RTI. Unfortunately, the study was 
terminated early due to difficulties in patient recruitment, 
resulting in inadequate statistical power to detect treatment 
differences. However, the data collected provided an oppor-
tunity to examine the course of AECOPD from diagnoses to 
week 12 in this little-studied patient population.
Methods
Original study design
TICARI 1 was a randomized, double-blind, placebo-controlled, 
parallel-group, multicenter, Phase IV trial to evaluate the effi-
cacy and safety of tiotropium in patients with acute RTI symp-
toms, who were either newly diagnosed with COPD at study 
entry or had a previous diagnosis and maintenance treatment 
naïve for $6 months pre-randomization. The study design is 
detailed in Figure 1. The study was conducted in the United 
States in primary care practices. Initial screening and case find-
ing were carried out at visit 0 (Supplementary materials [Meth-
ods section]). Patients, meeting all inclusion and no exclusion 
criteria, were randomized at visit 1 in a 1:1 ratio to tiotropium 
bromide 18 µg or placebo, delivered via HandiHaler® (Boeh-
ringer Ingelheim, Ingelheim, Germany). Doses were self-ad-
ministered once daily in the morning for 12 weeks, and patients 
were followed for an additional 30±3 days from the last dose. 
The target randomization sample size of 300 patients was not 
achieved, despite an enrolment period extension, resulting 
in inadequate power to achieve statistical significance in the 
primary efficacy endpoint, trough forced expiratory volume 
in 1 second (FEV
1
). Data from 140 subjects across treatment 
groups were available for exploratory analyses.
The study was approved by Chesapeake Research Review, 
Inc., Columbia, MD, USA (IRB00000790) and by the Institu-
tional Review Board at the University of Kentucky, Lexington, 
KY, USA (IRB00010346). All patients provided written 
informed consent for study participation.
sample
Study participants were male or female outpatients, aged $40 
years, with a history of smoking ($100 cigarettes over their 
lifetime) presenting to the clinic (outpatient setting) with 
acute worsening respiratory symptoms consistent with RTI 
for #7 days, including increase of previous or new shortness 
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of breath, or limitation of activities due to new/increased 
shortness of breath; and at least one of the following: 
1) increased chronic cough, new cough; 2) increased sputum 
production and/or color change; 3) nasal symptoms (conges-
tion, increased secretion, mucus amount, and/or color change); 
4) new/increased wheeze; 5) breathing-related chest discom-
fort; 6) new/increased nighttime awakenings from respiratory 
symptoms; 7) new/increased limitation of activities due to 
respiratory symptoms; and 8) elevated temperature ($37.8°C) 
at visit 0. AECOPD was defined as a patient-reported increase 
or new onset of more than one of the following respiratory 
symptoms: cough, sputum, sputum purulence, wheezing, and 
dyspnea for $3 days with clinician assessment and treatment 
with antibiotics and/or systemic steroids.
To confirm persistent airflow limitation, post-broncho-
dilator (four puffs of albuterol) FEV
1
/forced vital capacity 
(FVC) ,0.7 was assessed via pulmonary function tests at 
visit 1. In addition, a clinical assessment supporting both the 
diagnosis of COPD and introduction of maintenance therapy 
was required pre-randomization.
Key exclusion criteria included acute respiratory symp-
toms for .7 days pre-randomization; current asthma (subject 
treated for asthma in the last 2 years), cystic fibrosis, clinical 
diagnosis of bronchiectasis, interstitial lung disease, pulmo-
nary thromboembolic disease, or significant disease other 
than COPD; supplemental oxygen therapy for $24 con-
secutive hours during the 6 months pre-randomization; and 
participation in a pulmonary rehabilitation program. Patients 
were also excluded if they received COPD maintenance treat-
ment during the 6 months pre-randomization; specifically, 
therapy with any long-acting bronchodilator, short-acting 
anticholinergic, inhaled corticosteroid, or maintenance use 
of systemic corticosteroids for .14 consecutive days for 
respiratory indications.
Patients were issued an electronic diary (eDiary [In2itive™ 
device; Vitalograph, Maids Moreton, UK]) at visit 1, to use 
during the study.
During the study, patients received usual care for an 
acute RTI, including antibiotics and/or oral corticosteroids. 
They were also provided with rescue medication (open-label 
albuterol hydrofluoroalkanes metered-dose inhaler), which 
could be used at any time during the trial for symptom relief. 
Only the albuterol provided by the trial sponsor was allowed 
for rescue medication. Both study medication adherence and 
rescue medication use were recorded daily in the eDiary.
assessments
Pulmonary function testing
Spirometry was performed according to American Thoracic 
Society/European Respiratory Society standards,14 and 
predicted normal FEV
1
 values were calculated.15,16 Pre- and 
post-bronchodilator pulmonary function tests were per-
formed at visits 1 and 5. Peak expiratory flow rate (PEFR) 
and FEV
1
 were measured by the patient every evening using 
the integrated eDiary electronic peak flow meter. Spirometry 
measurements at visits 1 and 5 were used for Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) staging17 
(Supplementary materials [Methods section]).
eXaCT
Patients completed the EXACT, a patient-reported out-
come (PRO) measure, every evening in their eDiary prior 
to bedtime. This diary asks patients to rate the severity 
of 14 symptoms characteristic of an AECOPD, including 
breathlessness, cough, sputum, chest symptoms, sleep 
disturbance, feeling weak or tired, and feeling worried or 
concerned.18 Scores range from 0 to 100, with higher scores 
indicating a more severe health state.
Figure 1 study design.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic
 O
bs
tr
uc
tiv
e 
P
ul
m
on
ar
y 
D
is
ea
se
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
29
-J
an
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1518
Mannino et al
EXACT daily scores were used to characterize the exac-
erbation symptom trajectory over time, including patterns of 
recovery and relapse. Recovery was defined as a persistent, 
sustained decrease in score (ie, improvement) $9 points 
from the peak score observed during the first 14 days post-
randomization, maintained for 7 consecutive days, using a 
3-day rolling average beginning on Day 2. The first of the 
7 days was set as the recovery day. Relapse, assessed in 
patients who experienced a recovery, was defined as sus-
tained worsening following recovery (increased EXACT 
score $12 points for 2 consecutive days or $9 points for 
3 consecutive days above the mean recovery value).19 For 
evaluative purposes, EXACT change scores $5 points are 
considered meaningful with sustained improvements of this 
magnitude interpretable as recovering, although short of full 
recovery as defined earlier.
Other PrO measures
The COPD Assessment Test™ (CAT),20 Functional Assess-
ment of Chronic Illness Therapy–Short Form (FACIT-SF) for 
dyspnea and functional limitation,21 and Work Productivity 
and Activity Impairment Questionnaire: Respiratory Symp-
toms (WPAI:RS)22 were completed at visits 1–4.
The CAT20 is a disease-specific health status questionnaire. 
The test has eight items assessing cough, phlegm (mucus) 
production, chest tightness, breathlessness when going up 
hills/stairs, activity limitation at home, confidence in leaving 
home, sleep, and energy. Subjects rate each item on a scale of 
0–5; item responses are summed to yield a total score ranging 
from 0 to 40; where higher scores denote worse health status. 
The minimum clinically important change score is estimated 
to be 2 points,23 and a difference of 4.7 units between stable 
and exacerbating patients with COPD has been reported.20
The FACIT-SF for dyspnea and functional limitation21 
is a 20-item questionnaire with two components. One com-
ponent assesses dyspnea severity over the past 7 days while 
the second quantifies its effect on the performance of 10 
common everyday tasks. For severity, patients rate their 
dyspnea in relation to specific tasks, with scores ranging from 
0 (no shortness of breath) to 3 (severely short of breath). For 
functional limitation, patients describe how difficult it was to 
perform the tasks, with scores ranging from 0 (no difficulty) 
to 3 (much difficulty). For both the sections, if a task is not 
undertaken because of dyspnea it is scored 3, otherwise it is 
counted as a missing value. Raw scores for each section range 
from 0 to 30, which are converted to scale scores (dyspnea, 
27.7–75.9 and functional limitation, 29.7–76.7). The higher 
the score the worse the dyspnea or functional limitation.
The WPAI:RS22 assesses unpaid and paid work activity. 
This questionnaire asks respondents to report time missed 
from scheduled work due to respiratory symptoms, per-
centage of overall paid work impairment due to respiratory 
symptoms, and the percentage of regular activities impair-
ment due to respiratory symptoms (outside paid employment) 
over the previous 7 days.
safety and other assessments
Safety assessments included adverse event monitoring, physi-
cal examination, 12-lead electrocardiogram, and vital sign 
assessments. Smoking status was assessed at all visits, and 
concomitant medications taken #6 months before screening 
and throughout the study were recorded.
statistical analysis
Data from patients in both the treatment groups (n=140) were 
pooled for analyses. Because the study was underpowered 
for statistical testing, the primary analyses were descriptive. 
Symptomatic change was examined weekly over time using 
EXACT scores and rescue medication use; health status 
(CAT), dyspnea (FACIT-SF), and functional limitation (FAC-
IT-SF) were described at each clinic visit and change from 
baseline calculated. Lost work days, work impairment, and 
activity impairment over the 12-week treatment period were 
also assessed (WPAI). To further understand the patterns of 
symptomatic recovery, patients were stratified by symptom-
atic recovery status using the EXACT recovery rules (recov-
ered without relapse, recovered and then relapsed, and failed 
to meet the symptom improvement rule for recovery).
Categorical data are presented as number (%) and con-
tinuous data as mean (± standard deviation [SD]). Changes 
from baseline are presented as mean ± SD and adjusted 
mean changes from baseline as mean (± standard error [SE]). 
Finally, exploratory logistic regression analyses were per-
formed to assess the extent to which selected demographic 
and clinical characteristics (age, sex, smoking status, baseline 
FEV
1
, and treatment) may differentiate patients who recov-
ered from those who did not recover and those who relapsed 
from those who did not relapse.
Results
study population
Of the 266 patients enrolled in the trial, 47.4% failed screen-
ing (Figure S1). The most frequent reason (77.8%) for 
exclusion was failure to meet the trough FEV
1
/FVC ,0.70 
criterion. Overall, 140 patients were randomized and treated 
at 27 US centers. Treatment was completed by 95.7% of 
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patients, with a mean ± SD study medication compliance 
of 91.4%±13.2%. Study completion and compliance were 
similar between the treatment groups.
Baseline demographics and clinical characteristics of the 
analytical sample (N=140) and the recovery groups are shown 
in Tables 1 and 2. Most of the patients (73.6%) had a prior 
COPD diagnosis, and the date of prior diagnosis was known 
for 42.1% of patients; for these patients, the mean ± SD COPD 
duration was 1.05±1.75 years. The comorbidities experienced 
by the study patients were typical of those seen in the general 
COPD population, with the majority (97.9%) of patients having 
$1 comorbid condition. All patients were COPD maintenance 
treatment naïve prior to enrolment in the study. During the 3 
months pre-randomization, short-term pulmonary (non-main-
tenance therapy) medications were taken by 16.4% of patients, 
the most frequent were short-acting β
2
 agonists (SABA; 
11.4%) and oral corticosteroids (5.0%); other pulmonary 
medications were reported by ,3.0% of patients (Table S1).
Documentation of airflow obstruction and disease sever-
ity based on spirometry was obtained pre-randomization 
(visit 1) and at the follow-up (visit 5). Spirometric values 
were similar between visits, with most patients having GOLD 
stage II COPD17 (visit 1: 54.3%; visit 5: 51.1%; Table 1). The 
CAT20 and FACIT-SF for dyspnea and functional limitation21 
scores indicated impaired health status at baseline.
acute respiratory events and 
management
Acute respiratory events at visit 0 pertained to the acute 
symptoms that led to the patient’s clinic visit. Patients 
reported a mean ± SD duration of acute RTI symptoms pre-
randomization of 3.9±1.7 days. Of the symptoms specified 
as inclusion criteria, 80.0% of patients reported an increase 
in shortness of breath, 18.6% new shortness of breath, and 
78.6% limitation in daily activities due to new/increased 
shortness of breath. The frequency of additional symptoms 
are shown in Table S2. At baseline, 32.1% of patients met the 
criteria for COPD exacerbation as defined in the protocol.
At baseline (pre-randomization), 13.6% of patients were 
taking non-maintenance pulmonary medications; 11.4% were 
taking prednisone; other pulmonary medications were reported 
by ,2.0% of patients. (If a medication was started before 
informed consent [visit 0] and ended at or after the date of 
informed consent, it was considered as being used at baseline.)
Less than half of the patients (40.0%, n=56) reported 
taking active treatment for their RTI (within the 7 days before 
and after randomization). Of those who received treatment, 
34.3% reported corticosteroids (primarily prednisone), 32.1% 
Table 1 Baseline demographics and clinical characteristics
Characteristics Total group 
(n=140)
Male/female, n (%) 63 (45.0)/77 (55.0)
age, years, mean ± sD (range) 58.0±8.7 (40–83)
age groups, n (%)
,55 years 60 (42.9)
55–65 years 52 (37.1)
.65 years 28 (20.0)
race, n (%)
White 132 (94.3)
Black or african american 6 (4.3)
Other 2 (1.4)
ethnicity, n (%)
hispanic/latino 2 (1.4)
non-hispanic/latino 138 (98.6)
Body mass index, kg/m2, mean ± sD 27.8±7.1
ex-smoker/current smoker, n (%) 34 (24.3)/106 (75.7)
smoking history
Pack-years,a mean ± sD 46.3±30.9
$10 pack-years,a n (%) 132 (94.3)
employed, n (%) 57 (40.7)
Post-bronchodilator spirometry (visit 1), mean ± sD
FeV1, l 1.78±0.64
FeV1, % predicted 62.71±19.10
FVC, l 3.20±0.97
FVC, % predicted 91.75±19.68
FeV1/FVC 0.56±0.10
Prior physician COPD diagnosis at study 
entry, n (%)
103 (73.6)
COPD duration in patients with known date of 
prior diagnosis (n/n=59/103), years, mean ± sD
1.05±1.75
gOlD stage (visit 1/visit 5b), n (%)
I (mild) 24 (17.1)/18 (13.7)
II (moderate) 76 (54.3)/67 (51.1)
III (severe) 36 (25.7)/29 (22.1)
IV (very severe) 4 (2.9)/5 (3.8)
Unclassifiedc 0 (0)/12 (9.2)
Patients with concomitant diagnosis,d n (%) 137 (97.9)
hypertension 63 (45.0)
hyperlipidemia 47 (33.6)
Depression 41 (29.3)
anxiety 38 (27.1)
Gastroesophageal reflux disease 36 (25.7)
Osteoarthritis 31 (22.1)
CaT score, mean ± sD 23.8±7.6e
FaCIT-sF – dyspnea score, mean ± sD 53.6±9.4f
FaCIT-sF – functional limitation score, mean ± sD 51.6±9.8f
Notes: a1 pack-year represents 20 cigarettes per day for 1 year. bVisit 5: 
n=131. cAt visit 1 (baseline), 12 patients had airflow obstruction determined by 
spirometry, but on repeat spirometry at visit 5, they did not meet the gOlD 
criteria for airflow obstruction and were therefore unclassified. dMedical 
Dictionary for Drug regulatory activities (Medra) version 15.1 preferred terms, 
most frequently reported concomitant diagnoses ($20% of patients in either 
treatment group); patients may be included in more than one preferred term. 
en=98. fn=139. 
Abbreviations: CaT, COPD assessment Test™; FaCIT-sF, Functional assessment 
of Chronic Illness Therapy–short Form; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; gOlD, global Initiative for Chronic Obstructive lung 
Disease; sD, standard deviation.
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were treated with antibiotics, and 5% were on SABAs. 
Overall, the mean ± SD course of antibiotics was 7.2±2.7 days 
(range 2–14 days; median 7.0 days).
Medication use and symptoms by treatment group are 
shown in Tables S1 and S2, respectively, and results of the 
exploratory efficacy analyses for the effect of treatment on 
trough FEV
1
 and trough FVC are provided in Figure S2. Data 
for mean daily FEV
1
 and PEFR are shown in Table S3.
exacerbation recovery patterns
Over the 12 weeks of treatment, EXACT scores18 and rescue 
medication use showed similar patterns. EXACT scores 
declined over time from baseline (Figure 2A), indicating 
symptom improvement; the number of rescue medication 
puffs also declined (Figure 2B).
Mean CAT scores declined (health status improved) over 
time (Figure 3A). By week 2, the estimated minimum clinically 
important difference of a change from baseline of 2 CAT points23 
was reached (mean ± SD, -4.0±5.4) with continued improve-
ment thereafter (Figure 3B). According to the FACIT-SF, there 
were also trends for improvement in dyspnea (Figure 3C and 
D) and functional limitation (Figure 3E and F) over time; at 
week 12, mean ± SD changes from baseline were -5.3±8.2 for 
dyspnea and -4.2±7.5 for functional limitation. Trends were 
similar for the treatment groups (Figure S3A–F).
The 57 employed patients at baseline reported a mean ± SD 
number of lost working days over the 12-week treatment period 
of 5.23±8.45 days. Other WPAI:RS22 data are shown in Table S4.
symptomatic recovery and relapse
The mean ± SD peak EXACT score during the first 14 days 
of treatment was 49.7±12.1. Most of the patients (n=110, 
78.6%) exhibited an initial pattern of symptomatic recovery, 
with a mean recovery time from peak symptoms of 9.8 days 
(median 5.0 days; range 2–61 days). Although the tiotro-
pium group had a higher percentage of patients who initially 
recovered compared with placebo (80.9% vs 76.4%) and a 
shorter mean recovery time (8.7 vs 10.9 days), the study was 
underpowered to detect a difference.
Mean ± SD weekly EXACT scores declined during the first 
4 weeks following the initial clinic visit from 40.5±11.1 at week 
1 to 35.9±12.4 at week 4; the mean at week 12 was 36.0±13.6 
(Figure 2A). Mean ± SD weekly intraindividual variability in 
the EXACT score showed a trend for reduction over time from 
5.47±2.71 at week 1 to 3.66±2.74 at week 12.
Table 2 Pre- and post-bronchodilator pulmonary function and 
gOlD stage at visit 1 by exacerbation recovery pattern
Characteristics Recovered 
without relapse 
(n=69)
Recovered 
then relapsed 
(n=41)
No 
recovery 
(n=30)
Pre-bronchodilator spirometry, mean ± sD
FeV1, l 1.62±0.62 1.55±0.60 1.87±0.70
FeV1, % predicted 57.32±19.52 56.11±19.75 63.60±20.47
FVC, l 2.95±0.98 2.89±1.04 3.27±0.94
FVC, % predicted 84.07±21.53 85.43±24.23 90.95±20.45
FeV1/FVC ratio 0.55±0.09 0.54±0.11 0.56±0.11
Post-bronchodilator spirometry, mean ± sD
FeV1, l 1.77±0.63 1.67±0.61 1.96±0.69
FeV1, % predicted 62.59±18.93 60.20±19.95 66.41±18.35
FVC, l 3.20±1.00 3.01±0.88 3.46±0.98
FVC, % predicted 91.51±20.50 89.17±18.77 95.82±18.92
FeV1/FVC ratio 0.55±0.09 0.55±0.11 0.56±0.11
gOlD stage, n (%)
I (mild) 10 (14) 6 (15) 8 (27)
II (moderate) 40 (58) 20 (49) 16 (53)
III (severe) 18 (26) 13 (32) 5 (17)
IV (very severe) 1 (1) 2 (5) 1 (3)
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; gOlD, global Initiative for Chronic Obstructive lung Disease; 
sD, standard deviation.
Figure 2 Weekly mean ± se of daily (A) eXaCT scores and (B) number of rescue medication puffs.
Notes: shaded area represents the presumed pre-event mean ± se, based on week 12 data. solid line in A represents the 5-point change from the initial assessment.
Abbreviations: eXaCT, eXacerbation of Chronic Pulmonary Disease Tool; se, standard error.
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Of the 140 randomized patients, 49.3% (n=69) recov-
ered without relapse, 29.3% (n=41) recovered and then 
relapsed, and 21.4% (n=30) failed to meet the symptom 
improvement rule for recovery. Of the 110 patients who 
initially recovered, most (62.7%, n=69) remained stable 
during the 12-week study period. The pattern of recovery 
is supported by other objective indicators of relapse, col-
lected during the 12-week treatment period, including the 
frequency of follow-up visits for acute worsening of COPD 
(25.7%), a second exacerbation (12.9%), or escalation of 
therapy (3.6%).
In patients who recovered with no relapse, the daily mean 
EXACT score declined (improved) from baseline to around 
week 3, thereafter remaining relatively stable to week 12 
(Figure 4A). In contrast, patients who recovered and then 
relapsed (Figure 4B) or did not recover (Figure 4C) had 
more variable patterns of EXACT scores over the course of 
the 12-week treatment period.
The percentages of patients taking non-maintenance 
pulmonary medications within 3 months of study enrollment 
were 13.0% in the recovered without relapse group, 9.8% 
in the recovered and then relapsed group, and 20.0% in the 
Figure 3 exacerbation recovery patterns.
Notes: Descriptive statistics (mean ± sD) for the CaT and FaCIT – short Form scores for dyspnea and functional limitation over time (A, C, and E, respectively) and change 
from baseline (B, D, and F, respectively). For the CaT, only patients with COPD diagnosis before study entry were assessed.
Abbreviations: CaT, COPD assessment Test™; FaCIT, Functional assessment of Chronic Illness Therapy; sD, standard deviation.
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group who failed to meet the symptom improvement rule for 
recovery. In the 14 days prior to randomization, 33.6% of 
patients received treatment for their respiratory symptoms 
(31.9% in the recovered without relapse group; 29.3% in 
the recovered and then relapsed group, and 43.3% in the 
group who failed to meet the symptom improvement rule 
for recovery).
At baseline, 32.1% of patients met the criteria for a 
COPD exacerbation as defined in the protocol. In this sub-
group, the percentages of patients in each of the recovery 
groups were similar (recovered without relapse, 31.9%; 
recovered and then relapsed, 31.7%; and failed to meet the 
symptom improvement rule for recovery, 33.3%).
Exploratory logistic regression analyses suggested poor 
model fit for both recovery status (likelihood ratio chi-square 
4.39; P=0.49) and relapse status (likelihood ratio chi-square 
5.48; P=0.36) with no apparent signals for individual param-
eters (lowest significance (P) levels: 0.18 for FEV
1
 recovery 
status model and 0.12 for treatment relapse status model).
safety
No deaths were reported. Overall, 44.3% of patients reported 
adverse events; 41.2% on tiotropium; and 47.2% on placebo. 
No clinically notable mean changes in vital sign measurements 
occurred, and no trends were observed. During the study, 
six patients (4.3%; three patients per treatment group) had 
serious adverse events that required hospitalization. Further 
safety data are provided in Supplementary materials (Safety 
section) and Table S5.
Discussion
TICARI 1 aimed to assess the efficacy and safety of tiotro-
pium maintenance therapy compared with placebo in patients 
seen in an outpatient clinic with symptoms of an acute RTI, 
who were either newly diagnosed with COPD or had a prior 
COPD diagnosis but were maintenance treatment naïve. Due 
to recruitment difficulties, the study was underpowered to 
detect treatment differences. Descriptive data suggest that 
tiotropium was well-tolerated and showed an overall trend 
for clinical benefit. Data were pooled across treatment groups 
for an exploratory analysis of AECOPD recovery patterns 
in this little-studied patient group.
As a group, these maintenance treatment-naïve or newly 
diagnosed patients with COPD experienced symptomatic 
improvement over the study period with consistent patterns 
across outcome measures. Mean time from peak symptoms to 
recovery was 9.8 days (median, 5.0 days). These results are 
within the total symptom score recovery estimate for return 
Figure 4 Daily eXaCT scores (mean ± se).
Notes: (A) Patients who recovered without a subsequent relapse (n=69), (B) patients who recovered and then relapsed (n=41), and (C) patients who did not meet the 
symptom improvement rule for recovery (n=30).
Abbreviations: eXaCT, eXacerbation of Chronic Pulmonary Disease Tool; se, standard error.
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to baseline (exacerbation onset) of 7 days (interquartile range, 
4–14 days), reported by Seemungal et al,6 and are shorter 
than the AECOPD recovery times of 11–13 days reported 
by Aaron et al.7
Half of the patients in this sample either relapsed or failed 
to meet the criteria for symptomatic recovery with persistent 
elevated symptoms at week 12. In the group of patients who 
did not recover, a higher percentage (43.3%) had received 
treatments for their respiratory symptoms in the 14 days prior 
to randomization than patients who recovered without relapse 
(31.9%) and those who recovered and then relapsed (29.3%). 
Exploratory analysis showed that age, sex, smoking status, 
baseline FEV
1
, or treatment assignment was not associated 
with recovery or relapse status.
Relapse and persistent symptoms with AECOPD in 
diagnosed patients treated for COPD have been reported 
previously. Beauchesne et al24 reported a 29.5% failure 
rate with antibiotic treatment for AECOPD within 30 days 
from start of treatment. The study by Seemungal et al6 in 
COPD patients with moderate-to-severe airflow obstruction 
showed that recovery from an AECOPD was incomplete in 
a “significant proportion” of patients and suggested that, fol-
lowing ambulatory treatment for an AECOPD, relapse rates 
are 20%–25%.25 In our study of COPD patients who were 
maintenance treatment naïve, 29% of patients recovered and 
then relapsed and another 21% showed patterns consistent 
with persistent symptoms over 12 weeks. Symptom persis-
tence after an AECOPD has been associated with systemic 
inflammation.26 Furthermore, the presence of an AECOPD 
increases a patient’s susceptibility to having another, par-
ticularly in the high-risk period immediately following an 
AECOPD.27,28 Medical treatment of AECOPD events that 
includes pharmacologic therapy, patient education, and 
early follow-up treatment in cases of symptomatic relapse 
may reduce AECOPD frequency and improve short- and 
long-term outcomes.29
Although the mean peak EXACT score during the first 
14 days of treatment of 49.7±12.1 was similar to values seen 
in the original validation study for the EXACT (47.9±9.6 on 
day 1),18 it is lower than peak values observed in studies of 
moderate-to-severe COPD patients diagnosed and treated 
as outpatients for AECOPD (53.3±10.0 to 56.8±12.3),19 
suggesting that the undiagnosed and untreated patients in 
the current study were experiencing milder exacerbations 
with less room for improvement. It is possible that the 
9-point threshold to define recovery using the EXACT may 
be too stringent in milder patients or milder cases of RTI. 
At week 12, patients, on average, were symptomatic, with 
mean EXACT scores of 36.0±13.6 and mean CAT scores 
of 17.3±8.0, similar to values for stable patients reported 
previously.18,19 These results suggest that patients were 
symptomatic with impaired health status when stable and 
may have benefited from maintenance therapy.
Over half of the patients were GOLD stage II;17 many 
patients with mild airway obstruction may not seek medical 
attention, unless their symptoms impact their daily lives,30 
and many fail to seek medical attention for AECOPD.31 Pre-
vious studies of maintenance treatment-naïve patients with 
GOLD stage II COPD have shown improved lung function 
and reduced AECOPD risk when treated with tiotropium 
maintenance therapy.32,33 Pulmonary function testing at the 
time the patient is seen in the clinic for acute RTI symptoms 
is one approach for identifying undiagnosed cases of COPD 
and initiating patient education and maintenance therapy. 
Although our study was underpowered to detect treatment 
differences, numerical improvements in lung function and the 
trend toward shorter recovery time with tiotropium compared 
with placebo suggest that further study is warranted. Whether 
treatment initiation in newly diagnosed or treatment-naïve 
patients at the time of an acute RTI will lead to a reduction 
in risk of future AECOPD also needs evaluation. Previous 
research suggests this may be the case.34–37
The study had some limitations. Patients included in 
the study presented with symptoms of acute RTI and were 
evaluated clinically; however, no laboratory tests for specific 
pathogens were performed. At visit 1 (baseline), 12 patients 
had airflow obstruction determined by spirometry, but on 
repeat spirometry at visit 5, they did not meet the GOLD cri-
teria for airflow obstruction and were therefore unclassified. 
The patients had to demonstrate obstruction after four puffs of 
albuterol, thus excluding those patients with mild RTI-related 
bronchoconstriction. Patients with a history of smoking $100 
cigarettes over their lifetime was considered an inclusion crite-
ria; however, this level of smoking could be considered mild, 
as generally most patients thought to be at risk of COPD have 
a $10 pack-year smoking history. In this study, the proportion 
of patients with a ,10 pack-year smoking history was only 
5.7%. Furthermore, no association between smoking status 
(active vs former) and recovery status was observed.
Further investigation on the initiation of maintenance 
therapy in newly diagnosed or treatment-naïve patients and 
patterns of recovery from exacerbations in this population 
is warranted.
Conclusion
AECOPD recovery time for these newly diagnosed and 
maintenance treatment-naïve patients was at least 5 days, with 
around half experiencing relapse or persistent symptoms over 
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the 12-week follow-up. Further investigations are required to 
determine whether initiating COPD maintenance therapy dur-
ing an AECOPD could improve short- and long-term outcomes 
and reduce the risk of future AECOPD in this population.
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